American Journal of Cardiology
Volume 104, Issue 7 , Pages 936-942 , 1 October 2009

Effects of Consumption of Pomegranate Juice on Carotid Intima–Media Thickness in Men and Women at Moderate Risk for Coronary Heart Disease

  • Michael H. Davidson, MD

      Affiliations

    • Radiant Research and University of Chicago, Chicago, Illinois
    • Corresponding Author InformationCorresponding author: Tel: 312-494-2220; fax: 312-494-2217
    • ,
  • Kevin C. Maki, PhD

      Affiliations

    • Provident Clinical Research, Glen Ellyn, Illinois
    • ,
  • Mary R. Dicklin, PhD

      Affiliations

    • Provident Clinical Research, Glen Ellyn, Illinois
    • ,
  • Steven B. Feinstein, MD

      Affiliations

    • Rush Medical College, Chicago, Illinois
    • ,
  • MarySue Witchger, RD

      Affiliations

    • Provident Clinical Research, Glen Ellyn, Illinois
    • ,
  • Marjorie Bell

      Affiliations

    • Provident Clinical Research, Glen Ellyn, Illinois
    • ,
  • Darren K. McGuire, MD

      Affiliations

    • University of Texas Southwestern Medical Center, Dallas, Texas
    • ,
  • Jean-Claude Provost, MD

      Affiliations

    • Synarc Imaging, Paris, France
    • ,
  • Harley Liker, MD

      Affiliations

    • David Geffen School of Medicine, University of California, Los Angeles, California
    • ,
  • Michael Aviram, DSc

      Affiliations

    • Lipid Research Laboratory, Technion Faculty of Medicine and Rambam Medical Center, Haifa, Israel

Received 9 February 2009 ,Revised 13 May 2009 ,Accepted 13 May 2009.

References 

  1. Gil MI, Tomás-Barberán FA, Hess-Pierce B, Holcroft DM, Kader AA. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J Agric Food Chem. 2000;48:4581–4589
  2. Aviram M, Dornfeld L, Rosenblat M, Volkova N, Kaplan M, Coleman R, et al. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr. 2000;71:1062–1076
  3. Aviram M, Dornfeld L. Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure. Atherosclerosis. 2001;158:195–198
  4. Kaplan M, Hayek T, Raz A, Coleman R, Dornfeld L, Vaya J, et al. Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis. J Nutr. 2001;131:2082–2089
  5. Aviram M, Rosenblat M, Gaitini D, Nitecki S, Hoffman A, Dornfeld L, et al. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin Nutr. 2004;23:423–433
  6. Sumner MD, Elliott-Eller M, Weidner G, Daubenmier JJ, Chew MH, Marlin R, et al. Effects of pomegranate juice consumption on myocardial perfusion in patients with coronary heart disease. Am J Cardiol. 2005;96:810–814
  7. Ignarro LJ, Byrns RE, Sumi D, de Nigris F, Napoli C. Pomegranate juice protects nitric oxide against oxidative destruction and enhances the biological actions of nitric oxide. Nitric Oxide. 2006;15:93–102
  8. Rosenblat M, Hayek T, Aviram M. Anti-oxidative effects of pomegranate juice (PJ) consumption by diabetic patients on serum and on macrophages. Atherosclerosis. 2006;187:363–371
  9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  10. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006;296:2572–2581
  11. Gariepy J, Salomon J, Denarié N, Laskri F, Megnien JL, Levenson J, et al. Sex and topographic differences in associations between large-artery wall thickness and coronary risk profile in a French working cohort: the AXA study. Arterioscler Thromb Vasc Biol. 1998;18:584–590
  12. Simon A, Gariepy J, Moyse D, Levenson J. Differential effects of nifedipine and co-amilozide on progression of early carotid wall changes. Circulation. 2001;103:2949–2954
  13. Macioch JE, Katsamakis CD, Robin J, Liebson PR, Meyer PM, Geohas C, et al. Effect of contrast enhancement on measurement of carotid artery intimal medial thickness. Vasc Med. 2004;9:7–12
  14. Ledue TB, Rifai N. High sensitivity immunoassays for C-reactive protein: promises and pitfalls. Clin Chem Lab Med. 2001;39:1171–1176
  15. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. Anal Biochem. 1996;239:70–76
  16. Gan K, Smole A, Eckerson HW, La Du BN. Purification of human serum paraoxonase/arylesterase: evidence for one esterase catalyzing both activities. Drug Metab Dispos. 1991;19:100–106
  17. Frei B, Stocker R, Ames BN. Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci U S A. 1988;85:9748–9752
  18. El-Saadani M, Esterbauer N, El-Sayed M, Goher M, Nassar AY, Jurgens G. Spectrophotometric assay for lipid peroxides in serum lipoproteins using commercially available reagent. J Lipid Res. 1989;30:627–630
  19. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol. 1978;52:302–310
  20. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res. 1999;8:135–160
  21. Liu ML, Ylitalo K, Salonen R, Salonen JT, Taskinen MR. Circulating oxidized low-density lipoprotein and its association with carotid intima-media thickness in asymptomatic members of familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 2004;24:1492–1497
  22. Wallenfeldt K, Fagerberg B, Wikstrand J, Hulthe J. Oxidized low-density lipoprotein in plasma is a prognostic marker of subclinical atherosclerosis development in clinically healthy men. J Intern Med. 2004;256:413–420
  23. Carotid atorvastatin study in hyperlipidemic post-menopausal women: a randomized evaluation of atorvastatin versus placebo (CASHMERE). http://www.clinicalstudyresults.org/drugdetails/?drug_name_id=156&sort=c.company_name&page=2&drug_id=2902Accessed November 16, 2008
  24. Brown BG, Taylor AJ. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe. N Engl J Med. 2008;358:1504–1507
  25. Drazen JM, Jarcho JA, Morrissey S, Curfman GD. Cholesterol lowering and ezetimibe. N Engl J Med. 2008;358:1507–1508
  26. Kastelein JJP, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431–1443
  27. Stein EA. Additional lipid lowering trials using surrogate measurements of atherosclerosis by carotid intima-media thickness: More clarity or confusion?. J Am Coll Cardiol. 2008;52:2206–2209
  28. Poredos P. Intima-media thickness: indicator of cardiovascular risk and measure of the extent of atherosclerosis. Vasc Med. 2004;9:46–54
  29. Aviram M. Dietary antioxidants stimulate the expression of paraoxonases which provides protection against atherosclerosis development. Curr Top Nutraceutical Res. 2003;3:161–169
  30. Polagruto JA, Schramm DD, Wang-Polagruto JF, Lee L, Keen CL. Effects of flavonoids-rich beverages on prostacyclin synthesis in humans and human aortic endothelial cells: association with ex vivo platelet function. J Med Food. 2003;6:301–308

 This study was funded by Roll International Corporation, Los Angeles, California.

PII: S0002-9149(09)01104-7

doi: 10.1016/j.amjcard.2009.05.037

American Journal of Cardiology
Volume 104, Issue 7 , Pages 936-942 , 1 October 2009

Article Tools

* Image Usage & Resolution